Biotech IPOs in 2025: Quantity, quality, and best practices

For many private biotech companies, a successful initial public offering (IPO) remains a major aspiration as it can be a crucial catalyst for growth. It’s a move that can deliver vital funding for what are often the most capital-intensive stages of drug development: late-stage clinical trials, regulatory approval, and (eventually) commercial launch. It may also be an important way to create value for shareholders by delivering key derisking data as a public company. The public markets can therefore play a critical role in helping companies advance their most promising assets or technologies through these final miles. But unlocking access to these broader, and deeper, capital pools is not without challenges.

In this article, we discuss potential factors for success in a biotech IPO today — analyzing current market trends, key characteristics for a positive IPO trajectory, and best practices to sustain momentum as a public biotechnology company over time.